We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
MedXY AI/MedXY News/Tag: overall survival
MedXY News
EnglishTag

overall survival

Ask MedXY AI
type 2 diabetesclinical trialheart failureimmunotherapyobesitycardiovascular riskatrial fibrillationbiomarkerscritical careclinical trialsHypertensionartificial intelligenceCardiologyoncologypublic healthtype 1 diabetesdiabetesMortalityAlzheimer's diseasecardiovascular diseasebreast cancerepidemiology

Latest news

Tag

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study
Hematology-Oncologybệnh WilmsLymph node sampling

Lymph Node Assessment and Survival Outcomes in Favorable Histology Wilms Tumor: Insights from a Large COG Renal Tumor Study

By MedXY|Sep 13, 2026

This study evaluates how the number and positivity of lymph nodes affect survival outcomes in over 2,000 patients with stage I–III favorable histology Wilms tumor, underscoring the need for standardized lymph node sampling in surgical stagi

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis
Hematology-Oncology
multiple myeloma
MAIA trial

Long-Term Survival Benefit of Daratumumab with Lenalidomide and Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Insights from the MAIA Final Analysis

By MedXY|Aug 26, 2026

The MAIA final analysis establishes daratumumab plus lenalidomide/dexamethasone as a superior frontline regimen, significantly extending median overall survival to 7.5 years in transplant-ineligible newly diagnosed multiple myeloma patients

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial
DermatologyBRAF V600-mutant melanomaCOMBI-I trial

Long-Term Survival Benefit of Spartalizumab with Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma: Insights from the COMBI-I Trial

By MedXY|Aug 13, 2026

The COMBI-I trial demonstrates that adding spartalizumab to dabrafenib and trametinib improves overall survival in patients with BRAF V600-mutant advanced melanoma after over 6 years of follow-up, despite not meeting the initial progression

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial
Hematology-Oncologyfirst-line treatmentimmunotherapy

First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer: Secondary Analysis of the ASTRUM-005 Phase 3 Randomized Clinical Trial

By MedXY|Jun 7, 2026

Extended follow-up from ASTRUM-005 shows serplulimab plus chemotherapy improves long-term survival in untreated extensive-stage small cell lung cancer, with manageable safety and encouraging patient-reported outcomes.

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors
Hematology-OncologyClonal hematopoiesisoverall survival

Tumor-Infiltrating Clonal Hematopoiesis Emerges as a Pan-Cancer Prognostic Signal in Solid Tumors

By MedXY|May 9, 2026

A large whole-genome sequencing study found tumor-infiltrating clonal hematopoiesis in 18.4% of solid tumors, linked to older age, prior cytotoxic chemotherapy, and worse overall survival, with particularly strong associations in breast can

Adequate Lymph Node Dissection May Carry a Survival Signal in Intrahepatic Cholangiocarcinoma
General Surgeryintrahepatic cholangiocarcinomaLymph Node Dissection

Adequate Lymph Node Dissection May Carry a Survival Signal in Intrahepatic Cholangiocarcinoma

By MedXY|Apr 20, 2026

An updated meta-analysis suggests lymph node dissection in intrahepatic cholangiocarcinoma may improve survival when it is truly adequate, especially when at least six nodes are retrieved and confounding is reduced.

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data
Clinical Updatescamrelizumabimmunotherapy

Long-Term Survival Milestones in Metastatic Nasopharyngeal Carcinoma: A Comprehensive Review of the 5-Year CAPTAIN-1st Data

By MedXY|Mar 20, 2026

This review analyzes the 5-year overall survival outcomes of the CAPTAIN-1st trial, establishing camrelizumab plus chemotherapy as a long-term standard of care for recurrent or metastatic nasopharyngeal carcinoma.

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4
Hematology-OncologyCAR-T Therapycilta-cel

Cilta-cel Redefines Survival in Lenalidomide-Refractory Multiple Myeloma: Long-term Results from CARTITUDE-4

By MedXY|Feb 19, 2026

The updated CARTITUDE-4 analysis demonstrates that cilta-cel significantly improves overall survival and progression-free survival compared to standard therapies in lenalidomide-refractory multiple myeloma patients after the first relapse,

Systematic Complication Management Boosts Long-Term Survival in Pancreatic Cancer: Insights from the PORSCH Trial
General Surgeryoverall survival术后并发症

Systematic Complication Management Boosts Long-Term Survival in Pancreatic Cancer: Insights from the PORSCH Trial

By MedXY|Feb 16, 2026

A post-hoc analysis of the nationwide PORSCH trial reveals that algorithm-based care for early recognition and management of postoperative complications significantly improves long-term overall survival in patients undergoing pancreatic res

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma
newscamrelizumabimmunotherapy

Camrelizumab Plus Chemotherapy Sets a New Five-Year Survival Benchmark in Recurrent or Metastatic Nasopharyngeal Carcinoma

By MedXY|Jan 30, 2026

A secondary analysis of the CAPTAIN-1st trial reveals that adding camrelizumab to first-line chemotherapy significantly improves five-year overall survival in RM-NPC, with a 37.8% survival rate and notable benefits linked to rapid EBV DNA c

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial
newsoverall survivaltargeted therapy

Alectinib Sets a New Benchmark for Survival in ALK-Positive NSCLC: Final Results from the ALEX Trial

By MedXY|Jan 9, 2026

The final analysis of the Phase III ALEX trial confirms alectinib’s superior long-term efficacy over crizotinib, achieving a median overall survival of 81.1 months and significant intracranial benefits, solidifying its role as the fir

Distant Disease‑Free Survival Is a Reliable Surrogate for Overall Survival in Most Neoadjuvant Early Breast Cancer Trials — but Not All Subtypes
newsoverall survivalsurrogate endpoints

Distant Disease‑Free Survival Is a Reliable Surrogate for Overall Survival in Most Neoadjuvant Early Breast Cancer Trials — but Not All Subtypes

By MedXY|Nov 30, 2025

A pooled individual‑patient analysis of 11 neoadjuvant RCTs (12,247 patients) finds distant disease‑free survival (DDFS) strongly predicts overall survival (OS) trial‑level effects overall (R2trial=0.91), with weakened surrogacy in hormone‑

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results
Hematology-OncologyBCMAbelantamab mafodotin

Belantamab Mafodotin Plus Bortezomib and Dexamethasone Significantly Improves Overall Survival in Relapsed/Refractory Multiple Myeloma: Updated DREAMM-7 Results

By MedXY|Nov 4, 2025

The DREAMM-7 phase 3 trial shows that belantamab mafodotin combined with bortezomib and dexamethasone produces early, sustained, and statistically significant overall survival and deep, durable responses versus daratumumab-based therapy in

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer
newsageandrogen receptor pathway inhibitors

Age-Related Impact of Treatment Intensification on Survival in Metastatic Hormone-Sensitive Prostate Cancer

By MedXY|Oct 30, 2025

Systemic treatment intensification improves overall survival in metastatic hormone-sensitive prostate cancer, but its benefit varies by age and disease volume. Older men, particularly with low-volume disease, may have limited survival gains

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study
GastroenterologyBiliary tract cancercisplatin

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A 3-Year Survival Update from the Phase III TOPAZ-1 Study

By MedXY|Oct 29, 2025

The TOPAZ-1 study shows durvalumab combined with gemcitabine and cisplatin improves 3-year overall survival in advanced biliary tract cancer with manageable safety, establishing a new standard of care.

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival
GastroenterologyBiliary tract canceroverall survival

Evaluating Surrogate Endpoints in Advanced Biliary Tract Cancer: Progression-Free Survival Outperforms Response Rates as a Predictor of Overall Survival

By MedXY|Oct 28, 2025

This comprehensive analysis reveals that progression-free survival moderately correlates with overall survival in advanced biliary tract cancer, while objective response and disease control rates show poor correlation, underscoring the need

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib
OncologyeGFRNSCLC

Enhanced Survival in EGFR-Mutated NSCLC: Impact of Amivantamab-Lazertinib vs. Osimertinib

By MedXY|Oct 25, 2025

This article reviews a phase 3 trial comparing overall survival of amivantamab-lazertinib versus osimertinib in untreated EGFR-mutated advanced NSCLC, highlighting efficacy, safety, and clinical implications.

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma
Clinical Updatesdurvalumaboverall survival

Five-Year Survival Outcomes Confirm STRIDE’s Breakthrough in Unresectable Hepatocellular Carcinoma

By MedXY|Oct 8, 2025

The HIMALAYA trial demonstrates durable overall survival benefits and manageable safety of STRIDE (tremelimumab plus durvalumab) versus sorafenib in unresectable hepatocellular carcinoma after five years of follow-up.

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223
OncologyEnzalutamidemetastatic castration-resistant prostate cancer

Enhancing Outcomes in Metastatic Castration-Resistant Prostate Cancer: The EORTC 1333/PEACE-3 Trial of Enzalutamide Combined with Radium-223

By MedXY|Oct 8, 2025

The PEACE-3 trial demonstrates that adding radium-223 to enzalutamide significantly improves radiological progression-free survival and suggests an overall survival benefit in metastatic castration-resistant prostate cancer with bone metast

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials
Oncologyoverall survivalprostate cancer

Statin Use and Survival Benefits in Advanced Prostate Cancer Patients Receiving Apalutamide: Insights from the TITAN and SPARTAN Trials

By MedXY|Oct 4, 2025

Statin exposure is linked to improved overall survival in prostate cancer patients treated with apalutamide but raises the risk of severe cardiac adverse events due to underlying cardiovascular conditions.

1 / 2
12
Next
Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities